Associate Professor of Pharmacology and Cancer Biology
Our laboratory uses genomic and pharmacological approaches to understand how tumor dependencies are shaped by cell intrinsic factors, environmental factors, and drug treatments during the dynamic process of tumor evolution. To learn more, please visit our laboratory website: https://woodlabduke.com/.
Appointments and Affiliations
- Associate Professor of Pharmacology and Cancer Biology
- Associate Professor of Cell Biology
- Core Faculty in Innovation & Entrepreneurship
- Member of the Duke Cancer Institute
Contact Information
- Email Address: kris.wood@duke.edu
- Websites:
Education
- Ph.D. Massachusetts Institute of Technology, 2007
Courses Taught
- UPGEN 778D: University Program in Genetics and Genomics Biological Solutions Module IV
- UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I
- PHARM 818: Molecular Mechanisms of Oncogenesis
- PHARM 495: Research Independent Study
- PHARM 494: Research Independent Study
- PHARM 493: Research Independent Study
- MOLCAN 818: Molecular Mechanisms of Oncogenesis
- CMB 710D: Cell & Molecular Biology Module IV
- CMB 710B: Cell & Molecular Biology Module II
In the News
- Locking Leukemia's Cellular Escape Hatch (Jun 7, 2022 | Pratt)
- Cancer Repair Mechanism Could Be Potential Drug Target (Mar 31, 2022 | Duke Hea…
- Cancer Therapy Using Genetic Targeting and Gel Delivery Shows Promise (Sep 16, …
- From Innovation to Impact (Oct 3, 2018 | Duke Med Alumni News)
- Faculty Startup Sold to Belgian Pharma for $30 Million (Apr 9, 2018)
- Why Do Perfectly Good Cancer Treatments Suddenly Stop Working? (Oct 25, 2017 | …
- The Challenges of Combating Cancer Drug Resistance (Nov 18, 2015 | Duke Researc…
- Researchers Map Paths to Cancer Drug Resistance (Jan 4, 2015 | Duke Today)
Representative Publications
- Wu, Xingyu, Sendi Rafael Adame-Garcia, Keiichi Koshizuka, Pham Thuy Tien Vo, Thomas S. Hoang, Kuniaki Sato, Hiroki Izumi, et al. “Supplementary Figure 1 from Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism,” December 3, 2024. https://doi.org/10.1158/1940-6207.27951085.
- Wu, Xingyu, Sendi Rafael Adame-Garcia, Keiichi Koshizuka, Pham Thuy Tien Vo, Thomas S. Hoang, Kuniaki Sato, Hiroki Izumi, et al. “Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism.” Cancer Prev Res (Phila) 17, no. 12 (December 3, 2024): 571–83. https://doi.org/10.1158/1940-6207.CAPR-24-0124.
- Wu, Xingyu, Sendi Rafael Adame-Garcia, Keiichi Koshizuka, Pham Thuy Tien Vo, Thomas S. Hoang, Kuniaki Sato, Hiroki Izumi, et al. “Supplementary Figure 3 from Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism,” December 3, 2024. https://doi.org/10.1158/1940-6207.27951079.
- Wu, Xingyu, Sendi Rafael Adame-Garcia, Keiichi Koshizuka, Pham Thuy Tien Vo, Thomas S. Hoang, Kuniaki Sato, Hiroki Izumi, et al. “Supplementary Figure 4 from Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism,” December 3, 2024. https://doi.org/10.1158/1940-6207.27951076.
- Wu, Xingyu, Sendi Rafael Adame-Garcia, Keiichi Koshizuka, Pham Thuy Tien Vo, Thomas S. Hoang, Kuniaki Sato, Hiroki Izumi, et al. “Supplementary Figure 5 from Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism,” December 3, 2024. https://doi.org/10.1158/1940-6207.27951073.